Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

 are directly correlated with increased 30-year risk of cardiovascular disease among healthy women, according to a recent cohort study.

Elevated plasma lipoprotein(a) is a well-known risk factor for cardiovascular disease – lipoprotein(a) levels are predominantly determined genetically and stabilize within the first 2 years of life, which highlights its status as a lifelong independent risk factor for cardiovascular disease. However, few guidelines suggest consistent examination of lipoprotein(a) levels in healthy patients, potentially missing a swath of preventable cardiovascular diseases and deaths.

“Lifestyle intervention and currently available pharmacological treatment only modestly impact plasma lipoprotein(a) levels, and it remains to be demonstrated that isolated effective lipoprotein(a) lowering reduces risk of cardiovascular disease,” Daniel Chasman, PhD, division of preventive medicine, Brigham and Women’s Hospital, and colleagues wrote. “Consequently, contemporary guidelines do not consistently recommend lipoprotein(a) screening among individuals free from cardiovascular disease.”

Chasman and colleagues pulled patient data from the Women’s Health Study, an ongoing cohort study of initially healthy women recruited between 1992 and 1995 and followed up prospectively since 1993. The program initially intended to investigate the effects of low-dose aspirin on the risk of 

, first myocardial infarction, and death from cardiovascular causes. A total of 39,876 initially healthy women aged ≥45 years were included in the Women’s Health Study, who were then monitored for 10 years for a first major cardiovascular event.

Despite the trial’s conclusion in 2004, patients have been continuously followed up through January 2023. Chasman and colleagues therefore gathered blood samples from 28,345 women within the Women’s Health Study patient population. All women with available baseline lipoprotein(a) measurements were included; plasma lipoprotein(a) levels were measured in all baseline samples at once, and participants were grouped according to the following clinical thresholds and percentiles:

Percentiles were then grouped into the following categories:

The trial’s primary outcome was the first occurrence of a major cardiovascular event, including incident myocardial infarctions, 

, incident ischemic stroke, and death from cardiovascular causes. Secondary outcomes included fatal and nonfatal myocardial infarctions and fatal and nonfatal ischemic stroke, among others.

Of the 28,345 patients sampled, 27,748 patients had baseline lipoprotein(a) measurements and were included in the trial. During a median follow-up duration of 27.8 (interquartile range [IQR], 22.8-29.4) years, Chasman and colleagues noted 3707 incident major cardiovascular events, 1985 fatal or nonfatal coronary events, 1041 fatal or nonfatal ischemic stroke events, and 1543 cardiovascular deaths.

Investigators found that lipoprotein(a) levels >30 mg/dL or the 75th percentile (31 mg/dL) were associated with substantially increased 30-year risk of major cardiovascular events and coronary heart disease. Levels >120 mg/dL or the 99th percentile versus below the 50th percentile (11 mg/dL) were 1.54 (95% CI, 1.24 to 1.92) and 1.74 (95% CI, 1.35 to 2.25) for major cardiovascular events, 1.8 (95% CI, 1.36 to 2.37) and 2.06 (95% CI, 1.49 to 2.84) for coronary heart disease, 1.41 (95% CI, 0.93 to 2.15) and 1.85 (95% CI, 1.17 to 2.93) for ischemic stroke, and 1.63 (95% CI, 1.16 to 2.28) and 1.86 (95% CI, 1.26 to 2.72) for cardiovascular death.

“We believe our findings for 30-year cardiovascular risk support the case for screening for elevated lipoprotein(a) among healthy individuals, as recommended in some guidelines,” Chasman and colleagues wrote. “Most importantly, such screening could help identify individuals with very high lipoprotein(a) levels, as these individuals may benefit from primary preventive efforts, including possible future lipoprotein(a)-lowering therapies.”

Nordestgaard AT, Chasman DI, Moorthy V, et al. Thirty-year risk of cardiovascular disease among healthy women according to clinical thresholds of lipoprotein(a). JAMA Cardiology. Published online January 7, 2026. 

Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005;352(13):1293-1304. 

Articles

Elevated lipoprotein(a) levels are linked to a heightened 30-year cardiovascular disease risk in healthy women, as shown in a cohort study. Lipoprotein(a) is a genetically determined, lifelong risk factor, yet guidelines often overlook its screening. The study analyzed data from the Women’s Health Study, involving 28,345 women, revealing that levels above 30 mg/dL significantly increase cardiovascular event risks. Findings suggest that screening for elevated lipoprotein(a) could identify individuals who might benefit from preventive measures, including potential future therapies targeting lipoprotein(a) reduction.

A cohort study of patients from the Women’s Health Study has highlighted the direct correlation between lipoprotein(a) levels and cardiovascular risk in healthy patients.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Dyslipidemia

Very High Lipoprotein(a) Levels Linked to Cardiovascular Disease Among Healthy Women

Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for HCPLive. He is also the executive producer of two podcasts: Skin of Color Savvy and The Medical Sisterhood. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

A smartphone-based patient-caregiver eczema education intervention may help to reduce short-term disease relapse risk among young children with 

Despite this conclusion, the study also suggests effects of this intervention may diminish beyond 12 weeks of use. This analysis was authored by such investigators as Huan Yang, MD, PhD, of the Children’s Hospital of Chongqing Medical University’s Department of Dermatology. Through their work, Yang et al sought to investigate whether implementing a smartphone-based patient-caregiver educational program could lower eczema relapse rates in children aged 0 - 6 years.

The investigators highlighted the paradigm shift, resulting from the COVID-19 pandemic, toward a willingness among caregivers to utilize digital health tools.

 Consequently, a smartphone-based intervention was explored among this patient population.

“In this multicenter, randomized controlled trial (RCT), we aim to assess the efficacy of a smartphone-based digital educational program in comparison to conventional outpatient consultation alone on the relapse rates of [atopic dermatitis],” Yang and coauthors wrote.

The investigative team’s research was conducted within pediatric dermatology clinics located at 12 tertiary public hospitals across China. Their study involved a multi-center, parallel-group randomized controlled trial design (ChiCTR2000031474). Children between birth and 6 years of age with an atopic dermatitis diagnosis were recruited by the team in alignment with the American Academy of Dermatology Consensus criteria.

Patients were required, in order to be eligible for inclusion, to have moderate-to-severe atopic dermatitis. This was defined by Yang et al as a SCORAD score of 25 at minimum and an Investigator’s Global Assessment score of 3 or greater. A requirement was also in place necessitating a child’s primary caregiver as being both able to read Chinese and to operate a smartphone. They identified such patients during routine in-person outpatient visits.

The majority of those labeled as caregivers were parents, though grandparents made up a small proportion of the study subjects. Children recruited for the analysis were randomly placed into a 1:1 ratio, either in the intervention arm who received a smartphone-based digital education program in addition to usual care, or the study’s control arm, receiving standard outpatient consultation by itself.

A computer-generated sequence with a block size of 4 was used for the purposes of randomization. The study’s digital educational protocol was developed and managed via the oversight of an independent clinical research organization through a secure cloud-based system. This organization was separate from Yang and colleagues’ team of investigators.

Using a WeChat app-based Skin Care E-Station platform for its delivery, the intervention involved a 12-week program. The intervention’s content included structured educational modules in multimedia formats, with interactive learning tools and an electronic action plan personalized and adjusted for the child’s age and the severity of their eczema. The study’s main outcome measure was the rate of relapses at the 12-week mark following completion of acute treatment.

In their study’s secondary outcomes, Yang and coauthors looked at any shifts in disease severity, evaluated via the Scoring Atopic Dermatitis index, the Patient-Oriented Eczema Measure, and the Peak Pruritus Numerical Rating Scale. They also examined participants’ health-related quality of life using the Children’s Dermatology Life Quality Index or Infant’s Dermatitis Quality of Life Index and the Dermatitis Family Impact questionnaire. Follow-up interactions with participants extended to 52 weeks.

Results After Using Digital Eczema Education Tool

There were 615 children randomized, and the participants had a mean age of 3.3 years (SD 1.7).

 51.5% of the study subjects were listed as male. Relapses at the 12-week mark took place significantly less often in the digital education cohort versus the control cohort. Specifically, Yang and colleagues found relapses occurred in 16.6% versus 24.0% of those evaluated, respectively (relative risk 0.69, 95% CI 0.50–0.96; 

In their Kaplan–Meier analysis, Yang et al observed improved relapse-free survival within the initial 100 days in subjects given the digital intervention (hazard ratio 0.688, 95% CI 0.490–0.966; 

 There was no statistically significant difference seen between study arms in terms of relapse rates beyond 12 weeks or for secondary outcome measures. The team’s data regarding usage indicated strong engagement with the digital intervention. Specifically, they found 58.0% of caregivers continued to access this digital platform on a regular basis each week.

“Our findings are consistent with prior evidence demonstrating that structured education improves short-term management and adherence in pediatric [atopic dermatitis],” the investigative team concluded.

 “However, they also highlight a common challenge: achieving long-term disease modulation with brief interventions is difficult.”

Yang H, Shu H, Wang H, et al. Smartphone-Based Digital Eczema Education Program for Atopic Dermatitis in Children Aged 0 to 6 Years: Multicenter, Randomized, Parallel Controlled Clinical Study. J Med Internet Res. 2026 Jan 7;28:e79559. 

Golinelli D, Boetto E, Fantini MP, et al. Adoption of Digital Technologies in Health Care During the COVID-19 Pandemic: Systematic Review of Early Scientific Literature. J Med Internet Res. 2020 Nov 6;22(11):e22280. 

A smartphone-based educational intervention for caregivers of young children with moderate-to-severe atopic dermatitis may reduce short-term disease relapse risk. Conducted across 12 Chinese hospitals, the study involved a randomized controlled trial comparing digital education with standard outpatient care. Results showed a significant reduction in relapse rates at 12 weeks for the digital cohort, though effects diminished beyond this period. The intervention included multimedia educational modules and personalized action plans. Despite strong initial engagement, achieving long-term disease modulation remains challenging with brief interventions.

A smartphone-based patient-caregiver educational program was evaluated in its impact on relapse rates in children with moderate-to-severe atopic dermatitis.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Digital Eczema Education Decreases Relapse Rates in Children in the Short-Term

FDA Approves First Oral Preventive Treatment for Pediatric HAE, With Jolanta Bernatoniene, PhD

 has approved berotralstat (ORLADEYO) oral pellets for long-term prophylaxis of 

 in children aged 2 to 11 years. The approval, announced by BioCryst on December 12, 2025, marks the first and only oral, once-therapy indicated for long-term prevention of HAE attacks in this age group.

“Up until now, we had huge unmet needs for this patient group,” Jolanta Bernatoniene, PhD, lead investigator of the APeX-P trial in the United Kingdom and from Bristol Royal Hospital for Children, told 

“Those patients were managed with injections, and as you can imagine, those injections caused significant negative impact on the patients, on the families, [and] was difficult to manage from clinical perspectives.”

Historically, long-term prophylaxis in children relied on subcutaneous monoclonal antibodies, such as lanadelumab or intravenous C1 esterase inhibitor concentrates, both of which can be challenging for pediatric patients and caregivers. Frequent injections are associated with needle anxiety, treatment reluctance, and substantial caregiver burden.

“[The berotralstat approval is a] significant achievement because these are little sprinkles, very easy to administer,” Bernatoniene continued.

Berotralstat’s oral formulation offers a meaningful shift in care. The medication is administered as small pellets that can be sprinkled onto non-acidic food, simplifying dosing and improving treatment acceptance. Berotralstat is a substrate of P-glycoprotein (P-gp) and breast cancer resistance protein that can prevent HAE attacks by reducing the activity of the plasma kallikrein.

The FDA decision was supported by efficacy and safety data from the APeX-P trial, which evaluated weight-based dosing across pediatric age groups. Interim and long-term results demonstrated rapid and sustained reductions in HAE attack rates, with mean monthly attack rates reduced to 0, and more than half of patients remaining attack-free for up to 1 year. The interim data showed that, at a steady state, berotralstat reached peak concentration at a median of 3.9 hours (range, 0.9 – 6.0 hours).

No clinically meaningful differences in efficacy were observed across age, sex, or disease severity subgroups. Additionally, no cardiovascular safety concerns, including QT prolongation, were observed in the pediatric population, according to Bernatoniene. Ongoing extension studies will continue to monitor long-term safety and effectiveness for up to 5 years.

Clinicians anticipate that berotralstat’s approval will prompt updates to national and international HAE treatment guidelines and influence first-line prophylactic strategies for children, particularly younger patients for whom injectable therapies pose significant challenges.

When asked how the berotrolstat approval may impact future drug development, Bernatoniene said that there is always room for improvement. Although berotralstat is effective and easy to administer, it remains a once-daily treatment.

“[It] would be easier for the patients if we can administer [the treatment] less frequently, so perhaps oral formulation, but once a month or once every 3 months,” she said. “This is still [a] daily medication to remember for the family when they have very busy lives. Every drug will have its niche, so the indications and prescribing [have] to be discussed… in partnership with children age-appropriate and their families.”

Bernatoniene has no relevant disclosures.

Derman C. FDA Approves Oral Berotralstat for Children Aged 2 – 11 Years with HAE. HCPLive. December 12, 2025. Accessed January 15, 2026. 

https://www.hcplive.com/view/fda-approves-oral-berotralstat-children-aged-2-11-years-hae

BioCryst Announces FDA Approval of ORLADEYO® (berotralstat) Oral Pellets, First and Only Oral Prophylactic Treatment for Patients with HAE Aged 2 to <12 Years. BioCryst. Published December 12, 2025. Accessed December 12, 2025. 

https://ir.biocryst.com/news-releases/news-release-details/biocryst-announces-fda-approval-orladeyor-berotralstat-oral

Videos

Berotralstat becomes the first once-daily oral prophylactic option for long-term prevention of hereditary angioedema in children aged 2–11 years.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

FDA News

FDA Approves Oral Berotralstat for Pediatric HAE, With Jolanta Bernatoniene, PhD

Frances Lee, MD, is an assistant professor of medicine in the division of liver diseases at Mount Sinai.

Addressing Stigma and Advancing Care in Alcohol-Associated Liver Disease, With Frances Lee, MD

Alcohol-associated liver disease (ALD) remains a major and growing cause of liver-related morbidity and mortality, yet it is often approached through an oversimplified and stigmatized lens.

Misconceptions about who develops the disease, why it occurs, and how it should be treated continue to influence both patient engagement and clinical decision-making. As understanding of ALD evolves, there is increasing recognition that effective care extends beyond managing liver injury alone and requires a more nuanced, multidisciplinary approach.

“[It] is a really interesting topic because there are a lot of misconceptions both on the patient side and on the clinician side,” Frances Lee, MD, an assistant professor of medicine in the division of liver diseases at Mount Sinai, told 

, describing misinformed beliefs about comorbid alcohol use disorder and the subsequent stigmatization this thought process introduces.

For patients, she says this stigma may discourage engagement with care or delay presentation altogether, while for clinicians, it can unconsciously narrow how the disease is approached and managed.

Lee goes on to emphasize that ALD care involves more than just treating the liver disease–it also requires addressing factors impacting the patient’s drinking patterns. Because of this, she says multidisciplinary care is essential, like that provided by Mount Sinai’s Respectful and Equitable Access to Comprehensive Healthcare (REACH) Program.

Co-located within Mount Sinai Hospital’s Internal Medicine Associates, REACH provides a patient-centered, harm reduction approach to primary care for persons who use alcohol and other drugs, and for individuals living with hepatitis C virus infection. Similar programs exist at other institutions, like Massachusetts General Hospital’s Long-term Individualized Follow-up after Transplant (LIFT) Clinic for the the prevention and management of alcohol relapse in high-risk liver transplant recipients.

Beyond multidisciplinary care, Lee also looks ahead to the future of pharmacotherapy for ALD, describing her excitement about trials exploring GLP-1s and siRNA molecules for this indication.

“Right now, the current medications that we use for alcohol-associated liver disease are really medications for alcohol use disorder and alcohol use cravings, so to be able to offer patients a liver-specific therapy for their disease courses in the future is very exciting,” she said.

Editors’ Note: Lee does not report any relevant disclosures.

Mount Sinai. Respectful and Equitable Access to Comprehensive Healthcare (REACH) Program. Accessed January 15, 2026. 

https://www.mountsinai.org/care/primary-care/upper-east-side/ima/reach

Zhang W. Preventing Alcohol Relapse After Liver Transplant, with Wei Zhang, MD, PhD. 

. May 5, 2025. Accessed January 15, 2026. 

https://www.hcplive.com/view/preventing-alcohol-relapse-after-liver-transplant-with-wei-zhang-md-phd

Lee describes misconceptions about ALD, the importance of multidisciplinary care, and what the future of pharmacotherapy for this disease may hold.

Hepatology

Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

New research highlights persistent racial and ethnic disparities among patients with 

 undergoing kidney replacement therapy (KRT), with differences most pronounced in younger adults.

These findings reveal critical gaps across racial, ethnic, and age-based groups in mortality, transplantation, and dialysis modality use, although investigators stress the results do not imply causality.

“While the USRDS annual data report provides statistics by race/ethnicity or age separately, it lacks statistics on their interaction,” wrote study investigator Jonathan Daw, PhD, an associate professor of sociology and demography at the Pennsylvania State University, and colleagues. “To address this issue, it is important to assess if racial/ethnic groups vary in their age patterns of KRT receipt, which could imply critical periods for antidisparity interventions.”

Patients with kidney failure have several KRT options, including in-center dialysis, at-home dialysis, and kidney transplantation. Many patients experience multiple modalities over time, which can substantially affect quality of life and longevity. Although many patients prefer the convenience of home dialysis, in-center dialysis remains the most common option in the US.

Access to these modalities, particularly home dialysis and living donor kidney transplant (LDKT), varies across racial and ethnic groups. These disparities are influenced by systemic, social, and interpersonal factors, including 

. However, longitudinal differences in KRT modality transitions and duration across diverse populations remain underexplored. Sequence analysis is an emerging methodology enabling holistic depictions of patients’ longitudinal KRT experiences.

Building on this approach, Daw and colleagues conducted a sequence analysis using national registry data from the USRDS.

The exposures were race/ethnicity, including non-Hispanic Asian American (Asian-NH), non-Hispanic African American or Black (Black-NH), Hispanic, and non-Hispanic White (White-NH), as well as the age groups 18 to 44 years and 45 to 64 years. The primary outcomes were 10-year kidney replacement therapy modality sequences: in-center dialysis, home dialysis, deceased donor kidney transplant [DDKT], LDKT, stopped dialysis, and mortality.

Using sequence analysis, investigators characterized longitudinal KRT modality sequences using descriptive statistics and visualized them with state distribution plots stratified by race/ethnicity and age. No statistical significance tests were performed, with the reported differences reflecting real population-level patterns.

The cohort included 50,776 adults, with 24% aged 18-44 years and 76% aged 45-64 years. Racial/ethnic composition was 3.6% Asian-NH, 35.8% Black-NH, 17.7% Hispanic, and 42.9% White-NH. Specifically:

Asian-NH: 1,824 (478 aged 18-44; 1,346 aged 45-64)

Racial/ethnic differences in KRT modality and mortality were most pronounced in younger adults. By month 120, cumulative mortality was:

Among living patients, substantial differences in modality prevalence were observed. Functioning LDKTs were consistently most common in White-NH patients and least common in Black-NH patients:

Month 1: 6.5% Asian-NH, 1.4% Black-NH, 3.2% Hispanic, 8.7% White-NH

Month 120: 19.2% Asian-NH, 4.3% Black-NH, 12.4% Hispanic, 21.3% White-NH

For DDKTs, percentages by month 120 were similar across Black-NH, Hispanic, and White-NH patients (20.8%, 23.8%, 22.0%, respectively), but White-NH patients more often received DDKT earlier (month 49: 7.9% Black-NH, 8.9% Hispanic, 16.9% White-NH).

In-center dialysis use was increased among Asian-NH, Black-NH, and Hispanic patients than White-NH patients across the study period. Home dialysis use was increased among Asian-NH and White-NH patients compared with Black-NH and Hispanic patients in most periods.

Among 45-64-year-olds, racial/ethnic differences in KRT modality were attenuated due to increased prevalence of in-center dialysis. This age-leveling effect was even more pronounced in the 65-74 and 75+ age groups, where in-center dialysis and mortality dominate the KRT trajectory.

Sequence analysis revealed that the most common KRT modality sequence among 18-44-year-old Black-NH patients was in-center dialysis followed by mortality (C-M, 31.6%).

“Patterns in KRT modality sequences offer a more nuanced view of racial/ethnic disparities in access to treatments for incident kidney failure,” the investigators concluded. “Future research should investigate these data in a sequence analysis framework to better understand the determinants and consequences of racial/ethnic and age differences in KRT modality patterns,” concluded investigators.

Wilk AS, Cummings JR, Plantinga LC, Franch HA, Lea JP, Patzer RE. Racial and Ethnic Disparities in Kidney Replacement Therapies Among Adults With Kidney Failure: An Observational Study of Variation by Patient Age. 2022;80(1):9-19. doi:https://doi.org/10.1053/j.ajkd.2021.12.012

‌Pessin L, Roberts MK, Gillespie A, et al. Kidney Replacement Therapy Sequences: Racial/Ethnic Disparities in End-Stage Kidney Disease Patients’ 10-Year Treatment Histories. 

. 2025;8(2):101175. doi:https://doi.org/10.1016/j.xkme.2025.101175

Persistent racial and ethnic disparities exist among patients with kidney failure undergoing kidney replacement therapy (KRT), particularly in younger adults. These disparities manifest in mortality rates, transplantation, and dialysis modality use, influenced by systemic, social, and interpersonal factors. Sequence analysis of national registry data reveals significant differences in KRT modality sequences across racial/ethnic and age groups, with in-center dialysis being more prevalent among minority groups. The study emphasizes the need for targeted antidisparity interventions and further research to understand the determinants and consequences of these disparities in KRT patterns.

New sequence analysis suggests racial and ethnic disparities in KRT are pronounced in younger adults, affecting mortality, transplantation, and dialysis modality use.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Younger Adults Face Pronounced Racial, Ethnic Gaps in Kidney Therapy

Guy Young, MD, is the director of the Hemostasis and Thrombosis program at Children’s Hospital Los Angeles and professor of pediatrics at Keck School of Medicine of USC.

The SWITCH phase 1 trial aims to determine the optimal time to switch medications to minimize thrombotic risk and avoid leaving patients untreated.

Hematology

Ongoing Trial Investigates Switching from Emicizumab to Fitusiran in Hemophilia A, With Guy Young, MD

The Mortality Estimation in Renal Disease (MERD) score may help identify transplant candidates at highest risk of waitlist mortality.


New MERD Risk Score Predicts Mortality for Kidney Transplant Waitlist Patients

Ritlecitinib was evaluated for the treatment of non-segmental vitiligo (NSV) in different subgroups, stratified by demographics as well as various clinical characteristics.

Vitiligo

Vitiligo condition center page is a comprehensive resource for clinical news and insights on the dermatologic condition. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for the affected skin of vitiligo patients.

Ritlecitinib Efficacious for Non-Segmental Vitiligo Across Various Subgroups

Video Series

Clinical Experience with Tocilizumab and Upadacitinib in GCA Treatment 

Chelsie Derman is an associate editor for 

who covers psychiatry, sleep medicine, geriatrics, migraine, and allergy. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

Post-hoc analysis of the FLAME trial shows treatment discontinuation in COPD is associated with transient withdrawal effects and increased exacerbation risk.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

COPD

COPD condition center page, resources on the topics of medical news and expert insight into chronic obstructive pulmonary disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on COPD research, treatment, and drug development.

Stopping Inhaled Corticosteroids or LAMA in COPD Linked to Early Exacerbations

Reflecting on the Trial Landscape in GCA and History of Approved Agents 

Diana Isaacs, PharmD, is an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic.

Podcasts

Diana Isaacs, PharmD, and Natalie Bellini, DNP, are joined by Susan Weiner, MS, to discuss the recently released US Dietary Guidelines.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Type 2 Diabetes

Type 1 Diabetes

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Diabetes Dialogue

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives is a monthly podcast hosted by Diana Isaacs, PharmD, and Natalie Bellini, DNP, aimed at providing a regular roundup of the latest clinically applicable insights across diabetes and metabolic diseases, with a focus on leveraging technology to improve care.

Strategic Alliance Partnership

Diabetes Dialogue: Reviewing the New US Dietary Guidelines with Susan Weiner, MS

Once-daily treatment of atopic dermatitis with oral ICP-332 showed a favorable safety profile and meaningful efficacy in a new study.

ICP-332 Effective, Safe for Treating Moderate to Severe Atopic Dermatitis

Victoria Johnson joined the MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and now HCPLive. You can reach her at vjohnson@mjhlifesciences.com

Experts discussed how biologics revolutionize asthma and COPD management, emphasizing personalized treatment strategies and proactive care.

From GOLD to Ground Level: Navigating Biologic Use in COPD Care

A retrospective analysis does not link gentamicin with decreased risks of urinary tract infections after kidney transplantation.


Latest News

Very High Lipoprotein(a) Levels Linked to Cardiovascular Disease Among Healthy Women

Digital Eczema Education Decreases Relapse Rates in Children in the Short-Term

FDA Approves Oral Berotralstat for Pediatric HAE, With Jolanta Bernatoniene, PhD

Addressing Stigma and Advancing Care in Alcohol-Associated Liver Disease, With Frances Lee, MD

Younger Adults Face Pronounced Racial, Ethnic Gaps in Kidney Therapy